Luca Benatti

Track

Insider profile

Currently holds positions in Intercept Pharmaceuticals Inc and Newron Pharmaceuticals SpA

Performance

Overall performance
3.3
Performance over holding periods
3.3
30 days 90 days 120 days
Average return 8% 8.2% 15.1%
Success rate 63% 68% 82%
Transactions
2 50% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Independent Director Intercept Pharmaceuticals Inc July 1, 2014 -
Non-Executive Director Newron Pharmaceuticals SpA March 27, 2014 -
Chief Executive Officer, Managing Director, Member of the Management Board, Executive Director Newron Pharmaceuticals SpA Jan. 1, 1998 - May 31, 2012
Luca Benatti's trades of Quince Therapeutics, Inc.'s stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Proposed sale
Price
112.30
Quantity 55,504
Value US$4,372,320
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-12-29 2025-12-26
PrS Proposed sale
55,504
112.30
US$4,372,320 		55,504 112.30 US$4,372,320
2025-12-29 2025-12-26
S Sale
68,542 -38.6%
90.13
US$3,914,905 		68,542 -38.6% 90.13 US$3,914,905
2019-05-14 2019-05-14
B Purchase
27,834 -48.6%
245.06
US$491,991 		27,834 -48.6% 245.06 US$491,991